Targeting polo-like kinase 1 for cancer therapy

By K. Strebhardt, A. Ullrich. Nature Reviews. Cancer, 2006

858 citations recorded by the source corpus.

Subfields: Cell Biology, Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/ddc31f45cdab932172d8976925454c4955a8368f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cell Biology

In Molecular Biology

In Oncology

Citations in the corpus

Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle. (2008, background): “The identification of at least 2-fold upregulated phosphopep- Tyr15 of CDC2 (Ferrari, 2006; Meraldi et al., 2004; Strebhardt and Ullrich, 2006) (Figures 4A and 5).”
Cancer cells display profound intra- and interline variation following prolonged exposure to antimitotic drugs. (2008, background): “Front-runners include Eg5 kinesin inhibitors and inhibitors of mitotic kinases, such as the Auroras and Plk1 (Keen and Taylor, 2004; Bergnes et al., 2005; Strebhardt and Ullrich, 2006).”
Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy (2010, background): “The identification of PLK1 as a crucial, functional node in the oncogenic network, in which its inhibition results in systemic failure (that is, blockage of the tumorigenic state by apoptosis”
A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. (2009, positive): “Its activity is often deregulated in cancer cells and inhibitors against PLK1 have been developed as potential cancer therapeutics ( Strebhardt and Ullrich, 2006 ).”
Shared and separate functions of polo-like kinases and aurora kinases in cancer (2010, background): “PLK1 is essential for cell division, and its inhibition leads to a failure to complete mitosis, eventually resulting in cell deat”
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction (2009, positive): “undergoing clinical trials (Carpinelli and Moll, 2008; Strebhardt and Ullrich, 2006).”